Repligen Strengthens Cell Therapy Portfolio With BioLife Acquisition
Repligen to acquire BioLife Solutions for $1.5B to boost cell therapy bioprocessing capabilities and expand global reach.
Repligen is buying a company called BioLife Solutions to get better at making medicines that use special cells to help sick people. When a company buys another company to do things it wasn't good at before, watch to see if they actually work well together.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.